Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : wins FDA's breakthrough tag for lung cancer hopeful

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/06/2019 | 07:07am EDT
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.

(This story fixes typographical error in first paragraph.)

(Reporting by John Miller; Editing by Michael Shields and David Goodman)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
03:13pDR REDDY LABORATORIES : . Reddy's Suspends Shipments of Ranitidine
DJ
10:35aNOVARTIS : AveXis presents new data at EPNS continuing to show significant thera..
AQ
09/18NOVARTIS : Sandoz Halting Ranitidine Distribution
DJ
09/18NOVARTIS : halts distribution of its Zantac versions amid probe into impurities
RE
09/18NOVARTIS : Cosentyx positive 16-week PREVENT results advance potential new indic..
AQ
09/17NOVARTIS : Initiation of Novartis Entresto in-hospital included in the new ACC E..
AQ
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) -2-
DJ
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) Positive 16-week Prevent Results A..
DJ
09/16NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
AQ
09/14NOVARTIS : Trial and Error -2-
DJ
More news
Financials (USD)
Sales 2019 47 003 M
EBIT 2019 13 855 M
Net income 2019 10 274 M
Debt 2019 17 463 M
Yield 2019 3,44%
P/E ratio 2019 18,6x
P/E ratio 2020 20,3x
EV / Sales2019 4,58x
EV / Sales2020 4,22x
Capitalization 198 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,55  $
Last Close Price 86,26  $
Spread / Highest target 24,6%
Spread / Average Target 9,62%
Spread / Lowest Target -5,50%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS15.60%198 194
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.16.27%243 639
MERCK AND COMPANY9.89%214 995
PFIZER-16.36%201 939
NOVO NORDISK AS17.30%122 365